DXCM monthly performance report
Check DXCM's monthly returns, drawdown, and seasonality trends — updated every month.
DXCM monthly report
—
Key takeaways
- Dexcom (DXCM) closed September 2026 at $89.35, down 1.88% for the month and +17.91% over the trailing 12 months.
- Year-to-date, DXCM is +34.62%, outperforming the S&P 500 which has returned +11.70% YTD.
- The stock is trading +24.78% versus its 200-day moving average ($71.61), a bullish technical signal.
- Over the past three years, DXCM has underperformed the S&P 500 by −77.94%, with a relative strength index reading of 54.6.
- Win rate over the trailing 39 months stands at 46.2% — 18 positive months versus 21 negative months.
Dexcom ended September 2026 at $89.35, posting a monthly return of −1.88%. The S&P 500 returned −0.70% over the same window, leaving relative performance at −1.18%.
The current quarter stands at +32.67% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +24.78% versus the 200-day moving average ($71.61).
Year-to-date, DXCM is +34.62% against SPY +11.70%, a gap of +22.93%. The stock is currently −3.50% below its 52-week high, with maximum 3-year drawdown at −60.95%.
| Period | DXCM | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +1.61% | −0.12% | +1.73% |
| 1 Week | +7.61% | −0.34% | +7.95% |
| 1 Month | −1.88% | −0.70% | −1.18% |
| 3 Months | +22.13% | +2.80% | +19.33% |
| 6 Months | +39.09% | +13.85% | +25.24% |
| YTD | +34.62% | +11.70% | +22.93% |
| 12 Months | +17.91% | +15.01% | +2.89% |
| 3 Years | −6.24% | +71.69% | −77.94% |
| Rank | Month | Return |
|---|---|---|
| #1 | Nov 2023 | +30.05% |
| #2 | Jul 2026 | +23.90% |
| #3 | May 2026 | +23.83% |
| #4 | Mar 2024 | +20.54% |
| #5 | May 2025 | +20.20% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jul 2024 | −40.18% |
| #2 | Mar 2025 | −22.72% |
| #3 | Aug 2023 | −18.93% |
| #4 | Mar 2026 | −14.48% |
| #5 | Oct 2025 | −13.48% |
| Quarter | Return |
|---|---|
| Q2 2025 | +27.82% |
| Q3 2025 | −22.91% |
| Q4 2025 | −1.37% |
| Q1 2026 | −5.38% |
| Q2 2026 | +7.25% |
| Q3 2026 (QTD) | +32.67% |
| Year | Return |
|---|---|
| 2023 | +9.58% |
| 2024 | −37.33% |
| 2025 | −14.66% |
| 2026 | +34.62% |
| Metric | Value |
|---|---|
| 52-Week High | $92.59 (2026-08-24) |
| 52-Week Low | $54.11 (2025-11-07) |
| Current Price | $89.35 |
| 200-Day Moving Average | $71.61 |
| Price vs 200DMA | +24.78% |
| 3-Year Maximum Drawdown | −60.95% (2025-11-10) |
| Current Drawdown from 52W High | −3.50% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 54.6 |
| 3-Year Excess Return vs S&P 500 | −77.94% |
| RS Peak | 127.6 (Apr 2024) |
| RS Trough | 36 (May 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was DXCM's return for this report period?
DXCM returned −1.88% in the latest monthly window ending 2026-09-18.
Has DXCM outperformed SPY year to date?
YTD DXCM: +34.62% vs SPY: +11.70%.
What is DXCM's 12-month return?
+17.91% over the trailing 12 months.
Is DXCM above or below its 200-day moving average?
Price is +24.78% versus 200DMA ($71.61).
What is the maximum drawdown in the 3-year window?
−60.95% on 2025-11-10.